Fulvestrant, Inavolisib, and Palbociclib
About
Membership operator: AND
Therapies: 3
Therapies
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy group.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) FDA (2) | ER positive, HER2-negative, PIK3CA oncogenic variants | Invasive Breast Carcinoma | Fulvestrant, Inavolisib, Palbociclib | |
| EMA (1) FDA (2) | HER2-negative, PIK3CA oncogenic variants, PR positive | Invasive Breast Carcinoma | Fulvestrant, Inavolisib, Palbociclib | |
| EMA (1) FDA (2) | ER positive, HER2-negative, PIK3CA oncogenic variants, PR positive | Invasive Breast Carcinoma | Fulvestrant, Inavolisib, Palbociclib |